Brodalumab 210 mg + Placebo
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Axial Spondyloarthritis
Conditions
Axial Spondyloarthritis
Trial Timeline
May 1, 2015 → May 1, 2015
NCT ID
NCT02429882About Brodalumab 210 mg + Placebo
Brodalumab 210 mg + Placebo is a phase 2 stage product being developed by Amgen for Axial Spondyloarthritis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02429882. Target conditions include Axial Spondyloarthritis.
What happened to similar drugs?
6 of 20 similar drugs in Axial Spondyloarthritis were approved
Approved (6) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02429882 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 27 |
| Brodalumab + Placebo | Kyowa Kirin | Phase 3 | 40 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 40 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Upadacitinib | AbbVie | Pre-clinical | 33 |
| Adalimumab | AbbVie | Approved | 35 |
| Adalimumab + Placebo + Open-label Adalimumab | AbbVie | Phase 3 | 40 |
| adalimumab + Placebo | AbbVie | Phase 3 | 40 |
| Treatment | Merck | Pre-clinical | 66 |
| Golimumab | Merck | Phase 3 | 40 |
| Tulisokibart + Placebo | Merck | Phase 2 | 42 |
| Secukinumab 150 milligram [Cosentyx] | Novartis | Approved | 39 |
| secukinumab | Novartis | Pre-clinical | 26 |
| Secukinumab + Placebo | Novartis | Phase 3 | 40 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 47 |
| Secukinumab + Secukinumab and Placebo | Novartis | Phase 3 | 40 |
| Secukinumab/Adalimumab-Biosimilar | Novartis | Phase 3 | 40 |
| Etanercept 25mg + Sulfasalazine | Pfizer | Phase 2 | 31 |